Company / Financials
Kiniksa Pharmaceuticals International, plc Financials
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$677.6M
FY2025 · +60.1% YoY
Net Income
$59.0M
FY2025 · +236.6% YoY
Profit Margin
8.7%
FY2025 · net income / revenue
ROE
10.4%
FY2025 · return on equity
Total Assets
$763.6M
FY2025
Total Debt
-
FY2025
Equity
$567.6M
FY2025
ROA
7.7%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$677.6M+60.1% YoYNet Income HistoryProfit after all expenses and taxes$59.0M+236.6% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$77.7M+27.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes$77.2M+269.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$196.3M+16.8% YoYR&D Expense HistoryResearch and development spending$96.9M-13.2% YoYIncome Tax HistoryTotal income tax expense$29.9M+324.1% YoYEPS (Basic) HistoryBasic earnings per share$0.20-92.4% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$0.20-92.3% YoYShares Outstanding HistoryWeighted average diluted shares outstanding71.9M+2.1% YoY